Ionis Pharmaceuticals (IONS) said Monday that the company and partner AstraZeneca's (AZN) Wainzua received approval in the European Union to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, or ATTRv-PN.
Wainzua was approved for ATTRv-PN treatment in the US in December 2023 and has received approvals in other countries, including the UK and Canada, the company said.
ATTRv-PN results in peripheral nerve damage with motor disability within five years of diagnosis. Without treatment, the disease is "generally fatal" within 10 years, Ionis said.
Shares of Ionis rose 1.4% in recent premarket activity, while AstraZeneca fell 1.7%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.